CBU
SLNO

CIBC Bancorp USA’s Soleno Therapeutics SLNO Stock Holding History

CIBC Bancorp USA’s Portfolio SLNO Stock Details SLNO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$301K Buy
+4,452
New +$330K ﹤0.01% 1085

Other funds holding SLNO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

CIBC Bancorp USA's SLNO Position: Q3 2025 in Review

CIBC Bancorp USA opened a new position in Soleno Therapeutics (SLNO) in Q3 2025: 4,452 shares worth $301K. The stake represents ﹤0.01% of the portfolio and ranks #1085 among its holdings.

240 funds tracked by Wall St. Rank hold SLNO as of Q3 2025.

  • CIBC Bancorp USA held 4,452 shares of Soleno Therapeutics worth $301K as of Q3 2025.
  • Soleno Therapeutics was a new CIBC Bancorp USA position in Q3 2025.
  • Soleno Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2025, its #1085 holding.
  • 240 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q3 2025.

Based on CIBC Bancorp USA's 13F filing for Q3 2025, filed 12 Nov 2025.